EGb 761 in the Syndrome of MCI With Concomitant CVD
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed
clinical drug for patients with MCI + CVD. This study is an open label 52-weeks study in
subjects who have both MCI (based on the Petersen criteria and Albert MS criteria) and CVD.
Eligibility for enrolment will be assessed initially at a screening visit, which is to occur
within 42 days of baseline. 134 male and female subjects will participate and 67 of the 134
will receive the drug. Subjects will be randomized to the EGB 761 arm and control arm in a
1:1 ratio using a block randomization method in groups of 4 subjects using an automated
randomization software.
EGb 761 has been demonstrated to be useful in improving cognitive and global clinical
outcomes in patients with cognitive impairment or dementia, when administered at a daily
dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of
action. The study will allow generating data in an Asian and multi-racial population and
allows physicians to offer clinically efficacious and alternative treatment for patients with
MCI + CVD.